Lichen Planus and Beyond: A Review Of Erosive Noninfectious Skin Diseases

Ob Gyn News ◽  
2005 ◽  
Vol 40 (8) ◽  
pp. 26
Keyword(s):  
Biology ◽  
2021 ◽  
Vol 10 (11) ◽  
pp. 1129
Author(s):  
Anna Baran ◽  
Julia Nowowiejska ◽  
Tomasz W. Kamiński ◽  
Julita A. Krahel ◽  
Iwona Flisiak

Plaque psoriasis (PSO) and lichen planus (LP) are skin diseases with some similarities in pathogenesis, comorbidities, and clinical presentation. Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and its ligand, α4β7 integrin, are involved in inflammatory bowel diseases and liver dysfunctions, which occur more frequently in PSO and LP. Serum MAdCAM-1 and ITGB7 levels in patients with plaque PSO and eruptive LP have never been studied before. The study included 42 patients with PSO, 13 with LP, and 23 controls. Serum molecules levels were evaluated using the immune–enzymatic method. ITGB7 concentration was not statistically different, both in patients with PSO and LP, compared to controls (both p > 0.05). MAdCAM-1 level was significantly lower in PSO subjects than in controls (p = 0.041), whereas in the LP group, a downward trend was observed (p = 0.088) with p = 0.0455 in ANOVA. Multiple linear regression revealed independent associations between ITGB7 and HDL and BMI and RBC in the LP group. In psoriatic patients with elevated CRP, there was an upward trend for MAdCAM-1, and also a positive correlation between MAdCAM-1 and WBC. ITGB7 and MAdCAM-1 cannot serve as markers of disease activity or liver pathology neither in patients with PSO nor LP. MAdCAM-1 might play a role as an inflammation indicator in PSO and a beneficial influence on the lipid profile in LP.


2019 ◽  
pp. 44-51 ◽  
Author(s):  
Maitseo Nwako-Mohamadi ◽  
John Masenga ◽  
David Mavura ◽  
Ola Jahanpour ◽  
Eva Mbwilo ◽  
...  

Background: Papulosquamous skin diseases can be challenging to diagnose, especially in dark skin. Dermoscopy is reported to be helpful, but few data are available on its use in skin type IV or darker. Objective: To describe dermoscopic features in plaque-type psoriasis (PP), lichen planus (LP), and pityriasis rosea (PR) patients attending the Regional Dermatology Training Centre in Moshi, Northern Tanzania, and to compare findings with published data. Methods: A descriptive cross-sectional study was conducted at a tertiary hospital from October 2016 to June 2017. Fifty-six patients with PP, 25 with LP, and 9 with PR were enrolled consecutively. Clinical diagnosis was confirmed with histopathology in 74.4%. Dermoscopic vascular and nonvascular features from 225 lesions were analyzed. Results: Of the 90 patients enrolled, 58.9% were male and the median age was 50 (interquartile range 32.8-60.0) years. In PP lesions, red dots were found in 64.2% and white scale in 45.5%. In LP lesions the background was violet in 45.5% and 58.2% revealed Wickham striae. In PR lesions a dull red background was found in 50.0%, white scale in 83.3%, but no vessels were detectable. Conclusion: Dermoscopy features in PP, LP, and PR in dark skin are mostly similar to those in light skin.


Trials ◽  
2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Kristin Helene Skullerud ◽  
Petter Gjersvik ◽  
Are Hugo Pripp ◽  
Erik Qvigstad ◽  
Anne Lise Ording Helgesen

Abstract Background Genital erosive lichen planus (GELP) is a genital subtype of lichen planus, a chronic autoimmune inflammatory disease of unknown aetiology. In women, GELP is characterised by painful vulvo-vaginal mucosal erosions and scarring, often resulting in poor sexual health and reduced quality of life. Treatment options are limited and often with little effect. Apremilast, a phosphodiesterase 4-inhibitor, has been shown to have a positive effect on psoriasis and other inflammatory skin diseases. We aim to investigate the effect and safety of peroral apremilast in women with GELP in a randomised placebo-controlled double-blinded clinical trial. Methods We will recruit 42 adult women with characteristic clinical and/or histological features of moderate-to-severe GELP from a specialised vulva clinic in Oslo, Norway. The patients will be randomised 1:1 to either apremilast 30 mg BID (with an initial dose titration on days 1–6) or a placebo for 24 weeks. The concomitant use of topical corticosteroids will be allowed. The primary end point will be the mean GELP score, a clinical scoring system, at week 24 in the apremilast-treated patients versus the placebo-treated patients. The secondary end points will include the mean GELP score improvement from weeks 0 to 24, patient-reported use of topical steroids, the pain score on a visual analogue scale and the number of patients with GELP score improvements at weeks 16 and 24. The Physician Global Assessment , Patient Global Assessment and selected quality of life and sexual function assessments will be recorded at weeks 0, 16 and 24. The exploratory endpoints include description of immunohistochemical changes before and after apremilast therapy, assessed in vulvar or vaginal biopsies at weeks 0 and 24. Regular follow-ups for possible adverse events will be conducted. Discussion The study design is based on experience from studies on apremilast in other inflammatory skin diseases using equivalent apremilast doses for approved indications. The trial may provide evidence for the use of apremilast in women with this burdensome genital dermatosis. Trial registration ClinicalTrials.govNCT0365666. Registered on 4 September 2018.


2019 ◽  
Vol 95 (4) ◽  
pp. 31-39 ◽  
Author(s):  
A. Yu. Pashkin ◽  
A. S. Zhukov ◽  
V. R. Khairutdinov ◽  
I. E. Belousova ◽  
A. V. Samtsov ◽  
...  

Currently, it has been established that the cytokines of the IL-36 family occupy a significant place in the initiation and regulation of the inflammatory process in psoriasis.Objective: studying the expression level of IL-36γ cytokines in the skin of patients with plaque psoriasis.Material and methods. Skin biopsy specimens of 31 patients with plaque psoriasis were studied. The comparison group consisted of 20 biopsy samples of the skin of patients with lichen simplex, discoid eczema, lichen planus, mycosis fungoides (plaque stage). As a control group studied the skin bioptates of 10 healthy people. An immunohistochemical study of the skin was carried out using anti-IL-36γ antibodies.Results. An increase in the relative expression area of IL-36γ in the affected skin of patients with plaque psoriasis (7.4 %) was found, compared with the unaffected areas (0.10 %) and the control group (0 %). The expression of IL-36γ in the skin of patients with psoriasis in the progressive period (8.85 %) was 1.42 times higher than in the stationary period of the disease (6.2 %). A strong direct relationship was revealed (r = 0.71) between the level of IL-36γ expression in the affected skin and the value of the PASI index, a moderate direct relationship between the level of IL-36γ expression and epidermal thickness (r = 0.34). In the affected skin of psoriasis patients, expressed expression of IL-36γ was observed in the upper layers of the epidermis, patients of the comparison group (discoid eczema, lichen simplex, lichen planus, mycosis fungoides) were weak or moderate, in the unaffected areas of the skin of patients with psoriasis and healthy people — weak or absent.Findings. It was found that the expression of IL-36γ in the skin of patients with plaque psoriasis is significantly higher than with other skin diseases. The data obtained allow us to consider this cytokine as a possible diagnostic marker and use it in the differential diagnosis. 


2020 ◽  
Vol 36 (81) ◽  
pp. 1980-1994
Author(s):  
Marija Bradić-Vasić ◽  
Ana Pejčić ◽  
Milena Kostić ◽  
Ivan Minić ◽  
Radmila Obradović ◽  
...  

Introduction: Some of the typical skin diseases, such as Pemphigus vulgaris, Pemphigoid mucosae oris, Erythema exudativum multiforme, Sclerodremia, Dermatitis herpetiformis-Duhring and Lichen planus, can cause swelling and irritation in mucous membranes of the oral cavity. Aim: The aim of the study was to precise diagnosis and treatment of oral Lichen planus manifestations. Methods: Analyzing the literature data and the experience of clinicians, the most common oral lichen planus manifestations were investigated. Results: This disease most commonly occurs in middle-aged patients (30-60 years) and is more common in women than in men. Oral Lichen planus is rarely seen in children. The disease presents in 0.5% to 2% of the population. Clinical history established the relation between oral Lichen planus and oral carcinoma, and therefore this disease should be considered a precancerous lesion. Conclusion: Dermatoses in the mouth are localized most often in the oral mucosa, both at the height of the occlusal line and in the mucous membrane of the retromolar area, but they can also occur in the mucous membranes of the tongue, the floor of the mouth and lips.


Author(s):  
J. Vijaya Sree ◽  
V. Anand Kumar

<p class="abstract"><strong>Background:</strong> <span lang="EN-IN">Free radicals have an important involvement in the underlying mechanism of lichen planus (LP) and also various skin diseases. The aim of the study was to evaluate serum uric acid (UA) levels as a measure of the antioxidant defense status in lichen planus patients.</span></p><p class="abstract"><strong>Methods:</strong> <span lang="EN-IN">The duration of the present study was from September 2016 to October 2017 which includes 30 lichen planus patients and 30 other patients whose age and sex matched with the subjects served as controls</span>.<strong></strong></p><p class="abstract"><strong>Results:</strong> <span lang="EN-IN">Most common type of lichen planus is classical lichen planus. In our study, serum UA levels were significantly decreased in patients with respect to controls 3.1±0.91 and 4.9±1.08 mg/dl respectively. The difference of means is 1.8 mg/dl and was found to be significant (p&lt;0.001). </span></p><p class="abstract"><strong>Conclusions:</strong> <span lang="EN-IN">UA may be a potential, useful biomarker of antioxidant status in LP and a rational strengthening of the antioxidant defenses should be part of an optimal treatment strategy.</span></p>


2021 ◽  
Vol 12 (4) ◽  
pp. 33-38
Author(s):  
Manasa S ◽  
T N Mahesh ◽  
C V Rajashekhar

Skin disease makes as a great impact as other serious medical conditions when assessed by effects on health-related quality of life. There has been widespread acknowledgment that skin diseases can affect physical, social, and psychological aspects of patient’s everyday lives, as well as their partners, family, and friends, one such disease is Lichen planus. Lichen planus is a pruritic, benign, papulo-squamous, inflammatory dermatosis of unknown aetiology that affects either or all the skin, mucous membrane, hair, and nails. In its classical form, it presents with violaceous, scaly, flat topped, polygonal and papules. In classical texts of Ayurveda, the diagnosis is considered as Kitibha Kushtha. Kitibha Kushtha is vata and kapha dosha dominant condition in class of Kshudra Kushtha which has lakshanas like Shyava, Kina-khara sparsha, Parusha. Here, an effort was made to treat a thirty-eightyears old female diagnosed with Kitibha Kushtha vis-a-vis Lichen planus by classical Ayurveda regimens. She was administered with Shodhana therapies (bio-cleansing procedures) and then followed by intake of Thuvaraka rasayana and Shamana Aushadhis. The total duration of the treatment was 44 days, and the Study subject assessed before treatment and after treatment for improvement using Lichen planus Severity Index. All the symptoms observed in the beginning were found considerably reduced, and the severity also found mild.


2021 ◽  
Vol 12 (e) ◽  
pp. e85-e85
Author(s):  
G Rai Subodha Kumar ◽  
Nagesha Parvathi ◽  
RangeGowda Suresh ◽  
Rangaswamy Umadevi ◽  
Nirvanappa Vinay

Background: The incidence of Hepatitis C virus (HCV) infection among patients with Lichen planus (LP) varies considerably. There is also lack of data in Indian population. Due to these variation, this study is to assessing the prevalence of HCV infection among patients with CLP in Hassan Karnataka. Methods: 135 clinically diagnosed cases of Lichen planus more than 18 years of age will be included as cases.147 patients having skin diseases other than lichen planus will be included as controls. Details of the patients personal history and family history,medical history and blood transfusion history will be collected. Detection of antibodies against HCV (anti-HCV) by enzyme-linked immunosorbent assay (ELISA). Results: Anti-HCV antibodies were found in 3(2.2%) patients of the case group and 1(0.7%) in control group. P value is 0.274, not statistically significant. Conclusion: Currently, there is no evidence confirming the relationship between HCV infection and CLP in Hassan Karnataka. However, there is a need for further research on larger groups of


Sign in / Sign up

Export Citation Format

Share Document